SHL has extensive experience in the parenteral arena. In this article, SHL details its latest offerings in the world of biologics, as well as its partnership with speciality digital healthcare start-up QuiO to develop injectables in the connected healthcare space.
With autoinjectors delivering higher doses of proteins subcutaneously, there is the major consideration of injection duration. A duration of 10-15 seconds has historically been regarded as the maximum acceptable threshold for autoinjection. Patients typically prefer to not hold a device in place for any longer.
The complex molecular structure of biologics also poses a technical challenge. Biologics have a propensity towards destabilising or aggregating in a prefilled syringe or other primary packaging over the course of their shelf life.